Skip to main content
BTSG
NASDAQ Life Sciences

BrightSpring Posts Q3 EPS of 45 Cents

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$62.64
Mkt Cap
$11.915B
52W Low
$30.64
52W High
$73.75
52W Position info
104% above low
Off High info
15% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

BTSG has more than doubled off its 52-week low of $30.64.

Summary

BrightSpring reported third-quarter EPS of 45 cents, with revenue of $4.21B and adjusted EBITDA of $228M, up 42.0% from $160M a year earlier. Net revenue for the quarter was $4,213 million, up 26.4% from $3,334 million, gross profit rose 32.3% to $519 million, and net income from continuing operations was $101 million versus $38 million in Q3 2025; continuing operations diluted EPS was $0.46 and Adjusted EPS $0.54. The print follows Q2 revenue of $3.87B, up 23% year over year, with net income of $86.6M and leverage down to 2.15x after a $300M debt paydown; leverage stood at 1.79x as of September 30, 2026, compared to 2.15x on June 30, 2026. The company raised its full-year 2026 guidance to revenue of $15.9B-$16.125B and Adjusted EBITDA of $850M-$860M, with Pharmacy Segment Revenue of $14,000 million to $14,200 million and Provider Segment Revenue of $1,900 million to $1,925 million. Recent insider activity was routine: President Scott Greenwell sold 15,099 shares for about $874K under a pre-arranged 10b5-1 plan in mid-September, and the CEO had 36,355 shares withheld at $60.11 to cover taxes on vesting RSUs on October 27.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — BrightSpring raised full-year 2026 revenue guidance to $15.9B-$16.125B and Adjusted EBITDA guidance to $850M-$860M.

    • Q3 Results — Q3 2026 net revenue was $4,213 million, up 26.4%, with gross profit of $519 million. Net income from continuing operations was $101 million versus $38 million; Adjusted EBITDA $228 million, up 42.0%. Diluted EPS $0.45, continuing operations diluted EPS $0.46, Adjusted EPS $0.54.
    • Leverage — Leverage was 1.79x as of September 30, 2026, compared to 2.15x on June 30, 2026.
    • Segment Results — Pharmacy Solutions Q3 2026 revenue was $3,732 million, up 26%, with segment EBITDA of $202 million, up 43%. Provider Services revenue was $481 million, up 31%, with segment EBITDA of $79 million, up 30%.
    • Volume Metrics — Pharmacy prescriptions dispensed were 10,949,875, up 2%, with revenue per script of $340.86, up 24%. Home Health average daily census was 47,256, up 58%; Rehab Care persons served 7,574, up 9%.
    • Nine-Month Results — Nine-month 2026 revenue was $11,700 million, up 25%, and Adjusted EBITDA $623 million, up 44%. Net income was $333,118 thousand, diluted EPS $1.51 and Adjusted EPS $1.37.
    • 2026 Guidance — 2026 guidance: Pharmacy Segment Revenue $14,000 million to $14,200 million; Provider Segment Revenue $1,900 million to $1,925 million. The Amedisys and LHC branches acquisition is expected to contribute approximately $35 million in Adjusted EBITDA in 2026.
    • Cash Flow — Nine-month 2026 operating cash flow was $371,181 thousand and property and equipment purchases $72,666 thousand; long-term debt repayments $332,300 thousand and share repurchases $120,000 thousand. Cash was $717,840 thousand at September 30, 2026 versus $88,370 thousand at December 31, 2025; long-term debt $2,146,779 thousand versus $2,455,204 thousand.
    • Other Items — Nine months ended September 30, 2026 included a $101,845 thousand gain on sale of discontinued operations and $810,908 thousand in proceeds. Q3 2026 interest expense, net was $31,038 thousand versus $38,235 thousand; SG&A $358,069 thousand versus $304,165 thousand. Weighted average diluted shares were 220,226 thousand.
    All 21 details
    • Q3 2026 net revenue $4,213 million, up 26.4% from $3,334 million; gross profit $519 million, up 32.3% from $392 million.
    • Q3 2026 net income from continuing operations $101 million versus $38 million in Q3 2025.
    • Q3 2026 Adjusted EBITDA $228 million, up 42.0% from $160 million in Q3 2025.
    • Leverage 1.79x as of September 30, 2026, compared to 2.15x on June 30, 2026.
    • Q3 2026 diluted EPS $0.45; continuing operations diluted EPS $0.46; Adjusted EPS $0.54.
    • Nine-month 2026 revenue $11,700 million, up 25% from $9,360 million; Adjusted EBITDA $623 million, up 44% from $434 million.
    • Pharmacy Solutions Q3 2026 revenue $3,732 million, up 26% from $2,967 million; segment EBITDA $202 million, up 43% from $141 million.
    • Provider Services Q3 2026 revenue $481 million, up 31% from $367 million; segment EBITDA $79 million, up 30% from $61 million.
    • Pharmacy prescriptions dispensed 10,949,875, up 2% from 10,793,219; revenue per script $340.86, up 24% from $274.89.
    • Home Health average daily census 47,256, up 58% from 29,980; Rehab Care persons served 7,574, up 9% from 6,932.
    • 2026 guidance: Pharmacy Segment Revenue $14,000 million to $14,200 million; Provider Segment Revenue $1,900 million to $1,925 million.
    • Amedisys and LHC branches acquisition expected to contribute approximately $35 million in Adjusted EBITDA in 2026.
    • Nine-month 2026 net cash provided by operating activities $371,181 thousand; purchases of property and equipment $72,666 thousand.
    • Nine-month 2026 long-term debt repayments $332,300 thousand; repurchases of shares of common stock $120,000 thousand.
    • Cash and cash equivalents $717,840 thousand at September 30, 2026 and $88,370 thousand at December 31, 2025
    • Long-term debt, net of current portion: $2,146,779 thousand at September 30, 2026 and $2,455,204 thousand at December 31, 2025
    • Nine months ended September 30, 2026: gain on sale of discontinued operations $101,845 thousand; proceeds from sale of discontinued operations $810,908 thousand.
    • Q3 2026 interest expense, net $31,038 thousand versus $38,235 thousand in Q3 2025.
    • Q3 2026 selling, general, and administrative expenses $358,069 thousand versus $304,165 thousand in Q3 2025.
    • Nine months ended September 30, 2026: net income $333,118 thousand; diluted EPS $1.51; Adjusted EPS $1.37.
    • Weighted average diluted shares outstanding in Q3 2026: 220,226 thousand.

At the time of this announcement, BTSG was trading at $62.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $30.64 to $73.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

BTSG - Latest Insights

BTSG
Oct 30, 2026, 8:45 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.50
Real-time Price: $69.40 info
Change: +$4.90 (+8%) info
Market Cap: $13.819B info
BTSG
Jul 31, 2026, 8:45 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $73.00
Real-time Price: $69.40 info
Change: -$3.60 (-5%) info
Market Cap: $13.819B info
BTSG
Jul 31, 2026, 6:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $73.20
Real-time Price: $69.40 info
Change: -$3.80 (-5%) info
Market Cap: $13.819B info
BTSG
Jul 31, 2026, 6:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $72.12
Real-time Price: $69.40 info
Change: -$2.72 (-4%) info
Market Cap: $13.819B info
BTSG
Jun 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $63.23
Real-time Price: $69.40 info
Change: +$6.17 (+10%) info
Market Cap: $13.819B info